Reading Time: 2 minutesIntroduction Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a pivotal treatment for type 2 diabetes and obesity. Its efficacy in glycemic control and weight management is well-documented, but the long-term safety profile, particularly in American males, warrants a detailed examination. This article reviews the current evidence on the long-term safety of semaglutide, focusing on its implications for American men. Overview of Semaglutide Semaglutide is administered either weekly as an injection or daily as an oral formulation. It mimics the incretin hormone, which increases insulin secretion, decreases glucagon secretion, and slows gastric emptying, thereby aiding in blood sugar … Continue reading →